38 related articles for article (PubMed ID: 16309337)
1. Estimated generic prices of cancer medicines deemed cost-ineffective in England: a cost estimation analysis.
Hill A; Redd C; Gotham D; Erbacher I; Meldrum J; Harada R
BMJ Open; 2017 Jan; 7(1):e011965. PubMed ID: 28110283
[TBL] [Abstract][Full Text] [Related]
2. Use of budget savings from patent expiration of cancer drugs to improve affordability and accessibility.
Lee SM; Kim HJ; Suh D; Joung KI; Kim ES; Back HJ; Kwon JY; Park MJ; Suh DC
BMC Health Serv Res; 2021 Feb; 21(1):126. PubMed ID: 33549099
[TBL] [Abstract][Full Text] [Related]
3. Global Barriers to Accessing Off-Patent Endocrine Therapies: A Renaissance of the Orphan Disease?
de Silva NL; Dissanayake H; Kalra S; Meeran K; Somasundaram NP; Jayasena CN
J Clin Endocrinol Metab; 2024 Apr; 109(5):e1379-e1388. PubMed ID: 37846800
[TBL] [Abstract][Full Text] [Related]
4. Characteristics and outcomes of the drug patent linkage system in China.
Yao XF
Global Health; 2024 Apr; 20(1):31. PubMed ID: 38622631
[TBL] [Abstract][Full Text] [Related]
5. Concerns over expiry of some retained EU laws.
Vet Rec; 2023 Feb; 192(3):102. PubMed ID: 36734555
[No Abstract] [Full Text] [Related]
6. Budget and health impact of switching eligible patients with atrial fibrillation to lower- dose dabigatran.
Fens T; de Jong L; Kappelhoff B; Boersma C; Postma MJ
J Mark Access Health Policy; 2023; 11(1):2247719. PubMed ID: 37675057
[No Abstract] [Full Text] [Related]
7. What is the impact of intellectual property rules on access to medicines? A systematic review.
Tenni B; Moir HVJ; Townsend B; Kilic B; Farrell AM; Keegel T; Gleeson D
Global Health; 2022 Apr; 18(1):40. PubMed ID: 35428250
[TBL] [Abstract][Full Text] [Related]
8. Interrupted time-series analysis of the impact of generic market entry of antineoplastic products in China.
Guan X; Tian Y; Ross-Degnan D; Man C; Shi L
BMJ Open; 2018 Jul; 8(7):e022328. PubMed ID: 30012792
[TBL] [Abstract][Full Text] [Related]
9. The diffusion of generics after patent expiry in Germany.
Fischer KE; Stargardt T
Eur J Health Econ; 2016 Nov; 17(8):1027-1040. PubMed ID: 26573841
[TBL] [Abstract][Full Text] [Related]
10. A review of the health and economic implications of patent protection, with a specific focus on Thailand.
Yamabhai I; Smith RD
Health Res Policy Syst; 2012 Aug; 10():24. PubMed ID: 22849392
[TBL] [Abstract][Full Text] [Related]
11. The impact of generic substitution on the activities of pharmaceutical companies - a survey from the companies' perspective one year and five years after the introduction of generic substitution in finland.
Timonen J; Bengtström M; Karttunen P; Ahonen R
BMC Clin Pharmacol; 2010 Oct; 10():15. PubMed ID: 20964869
[TBL] [Abstract][Full Text] [Related]
12. Impact of European pharmaceutical price regulation on generic price competition: a review.
Puig-Junoy J
Pharmacoeconomics; 2010; 28(8):649-63. PubMed ID: 20515079
[TBL] [Abstract][Full Text] [Related]
13. Drug costs developments after patent expiry of enalapril, fluoxetine and ranitidine: a study conducted for the Netherlands.
Boersma C; Klok RM; Bos JM; Naunton M; van den Berg PB; de Jong-van den Berg LT; Postma MJ
Appl Health Econ Health Policy; 2005; 4(3):191-6. PubMed ID: 16309337
[TBL] [Abstract][Full Text] [Related]
14. Impact of the Minimum Pricing Policy and introduction of brand (generic) substitution into the Pharmaceutical Benefits Scheme in Australia.
McManus P; Birkett DJ; Dudley J; Stevens A
Pharmacoepidemiol Drug Saf; 2001; 10(4):295-300. PubMed ID: 11760489
[TBL] [Abstract][Full Text] [Related]
15. The Impact of Patent Expiry on Drug Prices: A Systematic Literature Review.
Vondeling GT; Cao Q; Postma MJ; Rozenbaum MH
Appl Health Econ Health Policy; 2018 Oct; 16(5):653-660. PubMed ID: 30019138
[TBL] [Abstract][Full Text] [Related]
16. Pricing policies for generic medicines in Australia, New Zealand, the Republic of Korea and Singapore: patent expiry and influence on atorvastatin price.
Roughead EE; Kim DS; Ong B; Kemp-Casey A
WHO South East Asia J Public Health; 2018 Sep; 7(2):99-106. PubMed ID: 30136668
[TBL] [Abstract][Full Text] [Related]
17. A Case Study of Pharmaceutical Pricing in China: Setting the Price for Off-Patent Originators.
Hu S; Zhang Y; He J; Du L; Xu M; Xie C; Peng Y; Wang L
Appl Health Econ Health Policy; 2015 Aug; 13 Suppl 1(Suppl 1):S13-20. PubMed ID: 26091710
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
